akerotx retweeted
📌In our January issue
A randomized, double-blind, placebo-controlled phase IIa trial of #efruxifermin for patients with compensated #NASHcirrhosis
🔓#OpenAccess at👉https://xitter.gq/t.co/7BegSiqWJs
#LiverTwitter
akerotx retweeted
#NASH drug R&D is marred by multiple clinical trial failures. @akerotx's Phase 2b win for #efruxifermin is notable because analysis was made w/ methodology FDA now requires for a new drug application in the fatty #liverdisease. $AKRO shares are up 120%+ medcitynews.com/2022/09/meta…
akerotx retweeted
Shares of @akerotx surged more than 104% in premarket trading after the announcement that efruxifermin improved liver fibrosis and prevented disease worsening in patients with pre-cirrhotic nonalcoholic steatohepatitis.
#AkeroTherapeutics #BioSpace
hubs.li/Q01mbx5g0
akerotx retweeted
$AKRO - Akero stock soars 71% as drug improves liver fibrosis, prevents disease worsening in trial seekingalpha.com/news/388223…
akerotx retweeted
Akero's efruxifermin hits key goals of mid-stage NASH study $AKRO firstwordpharma.com/story/56…
akerotx retweeted
Akero $AKRO treatment for NASH reduces liver scarring, achieves goals of mid-stage study statnews.com/2022/09/13/aker…
akerotx retweeted
🟪NEW Article in press❕
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH #cirrhosis
🔓#OpenAccess at👉https://xitter.gq/t.co/7BegSi9lkS
#nonalcoholicsteatohepatitis
#NALFD
#LiverTwitter
JANUARY ISSUE | CONSENSUS STATEMENT
Advancing the global public health agenda for #NAFLD: a consensus statement
FREE nature.com/articles/s41575-0…
#MAFLD #NASH #fattyliver #NoNASH
Our OCTOBER issue features this Expert Recommendation on defining comprehensive models of care for #NAFLD, the authors make 8 recommendations for the development of MOCs for NAFLD & #NASH
go.nature.com/3jxl94S
akerotx retweeted
#Thankyou for making International #NASHDay 2021 a resounding success. 🎉
Together, we continue to raise #awareness about #NASH & the actions that people can take to address this life-threatening disease.
🗓️Mark your Calendars: see you on June 9, 2022!
akerotx retweeted
NASH is the advanced version of #fattyliverdisease caused by fat build-up in the liver. What's your risk? #NASHawareness #LiverDisease #LiverExperts
akerotx retweeted
Efruxifermin an effective and safe treatment for nonalcoholic steatohepatitis dlvr.it/S3dDBK #ChronicDisease #Gastroenterology
akerotx retweeted
Will long-acting FGF21 analogs prove safe and sufficiently effective for #NASH @NatureMedicine nature.com/articles/s41591-0…
akerotx retweeted
Results from BALANCED, a phase 2a randomized controlled trial testing #efruxifermin (a long-acting FC-FGF21 fusion protein), demonstrated significant reductions in the #hepatic fat fraction in patients with F1-F3 stage non-alcoholic #steatohepatitis. #NASH
nature.com/articles/s41591-0…
akerotx retweeted
Hear @AASLDtweets member speakers Stephen Harrison, MD, FACP, FAASLD, Col (ret.) USA and Kenneth Cusi, MD, FACP, FACE speak on #NASH and #Diabetes during #NASHday
https://xitter.gq/t.co/bGlhpVazul
akerotx retweeted
June 10th is International #NASHDay. Join advocates & partners from across the🌐as we spread awareness about this serious #liverdisease that is on the rise. Together we can make our voices heard! Join the conversation🙌#NASHDay⮕https://xitter.gq/t.co/yxJboTAUGK #NAFLD #NASH @GlobalLiver
akerotx retweeted
“There has been a world of new data that has come forward relative to #diabetes & #fattyliverdisease in the past 12 months,” said Stephen A. Harrison, MD, FACP, FAASLD #NASHDay
akerotx retweeted
IT'S INTERNATIONAL #NASHDAY! We love raising awareness & fighting for our patients! Thanks to #AKERO for the beautiful props! #PinnacleProud #RaiseAwareness #InternationalNASHDay
























